ES3002745T3 - Multifunctional inhibitors of mek/pi3k and mtor/mek/pi3k biological pathways and therapeutic methods using the same - Google Patents
Multifunctional inhibitors of mek/pi3k and mtor/mek/pi3k biological pathways and therapeutic methods using the same Download PDFInfo
- Publication number
- ES3002745T3 ES3002745T3 ES22179630T ES22179630T ES3002745T3 ES 3002745 T3 ES3002745 T3 ES 3002745T3 ES 22179630 T ES22179630 T ES 22179630T ES 22179630 T ES22179630 T ES 22179630T ES 3002745 T3 ES3002745 T3 ES 3002745T3
- Authority
- ES
- Spain
- Prior art keywords
- cancer
- compound
- tumors
- pi3k
- inhibitors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662359001P | 2016-07-06 | 2016-07-06 | |
| US201762454163P | 2017-02-03 | 2017-02-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES3002745T3 true ES3002745T3 (en) | 2025-03-07 |
Family
ID=59363277
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES22179630T Active ES3002745T3 (en) | 2016-07-06 | 2017-07-06 | Multifunctional inhibitors of mek/pi3k and mtor/mek/pi3k biological pathways and therapeutic methods using the same |
| ES17740578T Active ES2922898T3 (es) | 2016-07-06 | 2017-07-06 | Inhibidores multifuncionales de las rutas biológicas de MEK/PI3K y mTOR/MEK/PI3K y métodos terapéuticos que usan los mismos |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES17740578T Active ES2922898T3 (es) | 2016-07-06 | 2017-07-06 | Inhibidores multifuncionales de las rutas biológicas de MEK/PI3K y mTOR/MEK/PI3K y métodos terapéuticos que usan los mismos |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10919877B2 (enExample) |
| EP (2) | EP4086250B1 (enExample) |
| JP (2) | JP2019519593A (enExample) |
| CN (1) | CN109563088B (enExample) |
| AU (2) | AU2017291838B2 (enExample) |
| CA (1) | CA3029875C (enExample) |
| ES (2) | ES3002745T3 (enExample) |
| WO (1) | WO2018009638A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018316175B2 (en) | 2017-08-11 | 2023-02-23 | The Regents Of The University Of Michigan | Inhibitors of MEK/PI3K, JAK/MEK, JAK/PI3K/mTOR and MEK/PI3K3k/mTOR biological pathways and methods for improving lymphatic uptake, bioavailability, and solubility of therapeutic compounds |
| CN112143700B (zh) * | 2019-06-26 | 2024-07-19 | 上海细胞治疗集团股份有限公司 | 制备过表达外源基因的免疫效应细胞的方法 |
| CA3154079A1 (en) | 2019-09-19 | 2021-03-25 | Totus Medicines Inc. | Therapeutic conjugates |
| MX2023011865A (es) * | 2021-04-09 | 2024-01-08 | Univ Basel | Derivados de triazina como inhibidores de pi3k covalentes reversibles e irreversibles. |
| CN117396470A (zh) * | 2021-04-09 | 2024-01-12 | 巴塞尔大学 | 作为pi3k的可逆和不可逆共价抑制剂的三嗪衍生物 |
| WO2023170107A1 (en) | 2022-03-07 | 2023-09-14 | Centre Hospitalier Universitaire Vaudois (Chuv) | Pi3k/akt/mtor inhibitor for improving the cellular uptake of a radiopharmaceutical |
| JP2023180347A (ja) * | 2022-06-09 | 2023-12-21 | 国立大学法人金沢大学 | ハイブリッド型化合物又はその塩 |
| CN116617227B (zh) * | 2023-06-09 | 2026-05-01 | 苏州大学 | 三氟噻吨在治疗脑血管疾病中的应用 |
| CN122070135A (zh) * | 2023-09-27 | 2026-05-19 | 托特斯医药公司 | 药物组合物及其使用方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA197701A (en) | 1920-03-02 | Mcgoldrick Timothy | Arm cushion for crutches | |
| CA85878A (en) | 1903-08-19 | 1904-03-08 | George W. Peyton | Carpenter's gauge |
| US5608110A (en) | 1993-06-15 | 1997-03-04 | Bracco International B.V. | Heteroatom-bearing ligands and metal complexes thereof |
| AU7349801A (en) | 2000-07-19 | 2002-01-30 | Warner Lambert Co | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids |
| TW200505834A (en) | 2003-03-18 | 2005-02-16 | Sankyo Co | Sulfamide derivative and the pharmaceutical composition thereof |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| AR059339A1 (es) | 2006-02-09 | 2008-03-26 | Chugai Pharmaceutical Co Ltd | Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene |
| CA2663401C (en) | 2006-09-15 | 2011-07-12 | Pfizer Products Inc. | Pyrido (2, 3-d) pyrimidinone compounds and their use as pi3 inhibitors |
| US8569378B2 (en) | 2007-07-20 | 2013-10-29 | Toshiyuki Sakai | p27 protein inducer |
| WO2009120094A2 (en) | 2008-03-27 | 2009-10-01 | Auckland Uniservices Limited | Substituted pyrimidines and triazines and their use in cancer therapy |
| JP5599783B2 (ja) * | 2008-05-30 | 2014-10-01 | アムジエン・インコーポレーテツド | Ｐｉ３キナーゼの阻害薬 |
| EP2143819A1 (de) | 2008-07-11 | 2010-01-13 | Siemens Aktiengesellschaft | Beschichtungsverfahren und Korrosionsschutzbeschichtung für Turbinen-Komponenten |
| CA2756067A1 (en) | 2009-03-27 | 2010-09-30 | Pathway Therapeutics, Inc. | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy |
| CA2767008C (en) | 2009-07-07 | 2018-01-30 | Pathway Therapeutics, Inc. | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy |
| US20110166191A1 (en) | 2010-01-07 | 2011-07-07 | Shijun Zhang | 3-(2-amino-ethyl)-5-(3-cyclohexyl-propylidene)-thiazolidine-2,4-dione and its derivatives as multiple signaling pathway inhibitors and for the treatment of cancer |
| GB201007227D0 (en) | 2010-04-30 | 2010-06-16 | Univ Basel | Piperazinotriazines |
| ES2570177T3 (es) * | 2010-08-10 | 2016-05-17 | Astellas Pharma Inc | Compuesto heterocíclico |
| WO2012068106A2 (en) | 2010-11-15 | 2012-05-24 | Exelixis, Inc. | Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture |
| AU2012257513B2 (en) * | 2011-05-19 | 2017-05-11 | Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) | Macrocyclic compounds as protein kinase inhibitors |
| EP2781520B1 (en) | 2011-11-17 | 2016-05-04 | Xuanzhu Pharma Co., Ltd. | Three-ring pi3k and/or mtor inhibitor |
| WO2014164942A1 (en) * | 2013-03-13 | 2014-10-09 | The Regents Of The University Of Michigan | Dual mek/pi3k inhibitors and therapeutic methods using the same |
| CN105283454B (zh) * | 2013-04-12 | 2019-10-29 | 阿萨纳生物科技有限责任公司 | 作为ras/raf/mek/erk和pi3k/akt/pten/mtor通路双重抑制剂的喹唑啉和氮杂喹唑啉 |
| CN105130960B (zh) * | 2015-07-31 | 2018-07-06 | 沈阳药科大学 | 1,3,5-三嗪类衍生物及其应用 |
-
2017
- 2017-07-06 JP JP2018568930A patent/JP2019519593A/ja active Pending
- 2017-07-06 WO PCT/US2017/040866 patent/WO2018009638A1/en not_active Ceased
- 2017-07-06 AU AU2017291838A patent/AU2017291838B2/en active Active
- 2017-07-06 CN CN201780049835.8A patent/CN109563088B/zh active Active
- 2017-07-06 US US16/313,923 patent/US10919877B2/en active Active
- 2017-07-06 ES ES22179630T patent/ES3002745T3/es active Active
- 2017-07-06 CA CA3029875A patent/CA3029875C/en active Active
- 2017-07-06 ES ES17740578T patent/ES2922898T3/es active Active
- 2017-07-06 EP EP22179630.3A patent/EP4086250B1/en active Active
- 2017-07-06 EP EP17740578.4A patent/EP3481822B1/en active Active
-
2021
- 2021-04-28 AU AU2021202619A patent/AU2021202619B2/en active Active
- 2021-11-24 JP JP2021190205A patent/JP7475062B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019519593A (ja) | 2019-07-11 |
| AU2017291838A1 (en) | 2019-01-17 |
| EP3481822A1 (en) | 2019-05-15 |
| WO2018009638A1 (en) | 2018-01-11 |
| EP4086250A2 (en) | 2022-11-09 |
| US10919877B2 (en) | 2021-02-16 |
| JP7475062B2 (ja) | 2024-04-26 |
| EP4086250B1 (en) | 2024-12-11 |
| AU2017291838B2 (en) | 2021-01-28 |
| AU2021202619B2 (en) | 2022-03-10 |
| JP2022019812A (ja) | 2022-01-27 |
| AU2021202619A1 (en) | 2021-05-27 |
| EP4086250C0 (en) | 2024-12-11 |
| CA3029875A1 (en) | 2018-01-11 |
| US20190224207A1 (en) | 2019-07-25 |
| EP4086250A3 (en) | 2023-03-22 |
| EP3481822B1 (en) | 2022-06-22 |
| CA3029875C (en) | 2023-12-19 |
| CN109563088A (zh) | 2019-04-02 |
| ES2922898T3 (es) | 2022-09-21 |
| CN109563088B (zh) | 2022-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2922898T3 (es) | Inhibidores multifuncionales de las rutas biológicas de MEK/PI3K y mTOR/MEK/PI3K y métodos terapéuticos que usan los mismos | |
| CA2901613C (en) | Dual mek/pi3k inhibitors and therapeutic methods using the same | |
| ES2826443T3 (es) | Inhibidores de proteínas mutantes KRAS G12C | |
| JP6789239B2 (ja) | Ｋｒａｓの縮合三環系インヒビターおよびその使用の方法 | |
| WO2011159685A2 (en) | Inhibition of wdr5 interaction with its binding partners and therapeutic methods | |
| US20250145617A1 (en) | Sigma-2 receptor ligand drug conjugates as antitumor compounds, methods of synthesis and uses thereof | |
| US20170166569A1 (en) | Asparagine Endopeptidase (AEP) Inhibitors for Managing Cancer and Compositions Related Thereto | |
| EP4460306A2 (en) | Targeting swi/snf related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4 (smarca4) | |
| JP2024538132A (ja) | Ｄｏｔ１ｌ分解のための小分子およびその使用 |